Navigation Links
New Data Presented on Micardis (Telmisartan) Tablets in,Hypertensive Patients With Type 2 Diabetes

RIDGEFIELD, Conn., June 18, 2007 /PRNewswire/ -- Today, results from AMADEO*, one of a series of studies comparing two angiotensin receptor blockers (ARBs) in hypertensive patients with diabetic nephropathy, were presented at the 17th annual European Meeting on Hypertension in Milan, Italy.

The randomized, double-blind, forced titration, parallel group, multicenter study included 860 hypertensive patients (>130/80mmHg) with type 2 diabetes and overt nephropathy from 124 centers in 10 countries. Patients were randomized to receive treatment with either Micardis (telmisartan) 80mg or losartan 100mg. To ensure blood pressure control in the two patient groups, other non-ARB treatments (hydrochlorothiazide or a calcium channel blocker) were added, if needed.

No significant difference in blood pressure control or number of adverse events was observed between the two treatment groups.(1)

After treatment of one year, 24 hour protein excretion measured by spot protein to creatinine ratio was reduced by 29% with Micardis (telmisartan) vs. 20% with losartan (p= 0.0284).(1)

At baseline proteinuria was similar for both groups. The change from baseline after 12 months (log transformed Urinary Protein creatinine ratio) was 0.71 for Micardis (telmisartan) vs. 0.80 for losartan (p=0.0284)(1) [Micardis (telmisartan) 0.71 (95% CI; 0.66, 0.77) vs. losartan 0.80 (95% CI; 0.74, 0.87)].(1)

Proteinuria (high levels of protein in the urine) is a very important signal for disease severity in diabetic nephropathy and is also considered a relevant cardiovascular risk factor. Renal outcomes trials have shown that reductions in proteinuria of >30% at six months are strongly linked to slowed progression to end-stage kidney disease and reduced cardiovascular events.(2)

AMADEO* concludes a series of studies which are part of an extensive ongoing trial program, with several clinical studies, as well as
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and Maintenance vs. Placebo
Post Your Comments:
(Date:7/24/2014)... DALLAS , July 24, 2014  Market ... of IVD Insights™ LabFile , a data ... the US clinical laboratory universe and identifying target ... is a proprietary database that provides IVD manufacturers ... clinical tests, relying on clear and consistent definitions ...
(Date:7/24/2014)... 24, 2014 HIGHLIGHTS:Q2 2014 Results (all ... , Reported sales increased 3% to $701 million.  Sales grew ... added one percentage point to sales growth. , By ... in Applied and 1% in SAFC Commercial. , Reported ... an increase of 13%.  Adjusted diluted EPS in Q2 2014 ...
(Date:7/24/2014)... DIEGO , July 24, 2014   ... announced today a co-promotion agreement with Illumina to ... genome sequence data for precision medicine and clinical ... pharmaceutical companies, through Illumina,s sales force, a solution ... platform for data analytics and storage, and Cypher ...
Breaking Medicine Technology:MDxI Launches Data Resource Setting New Standard for Defining and Targeting US Clinical Laboratory Universe 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 4Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 5Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 6Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 7Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 8Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 9Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 10Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 11Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 12Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 13Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 14Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 15Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 16Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 17Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 18Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 19Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 20Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 21Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 22Cypher Genomics and Illumina Enter Agreement to Facilitate Genomic Biomarker Discovery 2Cypher Genomics and Illumina Enter Agreement to Facilitate Genomic Biomarker Discovery 3
... Alpharma Inc.,(NYSE: ALO ), a ... its Phase III pivotal efficacy trial that ... naltrexone,hydrochloride) capsules provided significant pain relief in ... osteoarthritis of the hip or knee compared,to ...
... Ardea Biosciences, Inc.,(Nasdaq: RDEA ) today announced ... mitogen-activated ERK kinase (MEK) inhibitor, RDEA119,at the American College ... & Convention Center in Orlando., ... October 7, 2008 from 10:30 a.m. - 4:00 p.m. ...
Cached Medicine Technology:Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 2Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 3Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 4Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 5Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting 2
(Date:7/24/2014)... 2014 Angeldress.co.uk, a renowned wedding dress ... ladies to obtain their dream garments at affordable prices. ... special occasion outfits for clients from all over the ... latest designs and the information on how to choose ... Recently, the company has unveiled its new collection of ...
(Date:7/24/2014)... Discount-Dress.com, an innovative company that provides ... outfits, is doing its best to attract new clients. ... rates, up to 75% off. Recently, the company has ... Also, it has unveiled many new products for ladies ... lace wedding dresses, purple prom dresses and so forth. ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 A study ... Pediatrics was conducted by Dr. Shonna Yin of NYU’s Langone ... poison centers each year are due to confusion over liquid ... recommended dosage amounts for adults versus children, Yin warns it ... , When tested, roughly 40 percent of parents in the ...
(Date:7/24/2014)... July 24, 2014 American Sentinel ... Identify and Prevent the Three Infections That Make ... is a go-to guide to help nurses minimize ... and details basic prevention measures that every nurse ... is available for download at http://www.americansentinel.edu/blog/2014/05/13/strong-nursing-leadership-is-essential-to-reducing-hais/ . ...
(Date:7/24/2014)... Crawford Technologies today announced the results ... AIIM, focusing on global trends in high-volume transactions ... survey indicated that even though organizations stated the ... service, legal and regulatory compliance and historical record ... facsimiles of these documents. , The survey found ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk, A Renowned Wedding Dress Manufacturer And Retailer, Vows To Offer The Best Bridesmaid Dresses For Ladies 2Health News:Discount-Dress.com Announces the Launch of Its New Blog and Publishes Articles About Its Fabulous Special Occasion Dresses 2Health News:Many Parents Confused by Over-The-Counter Medications and OTCPlus App Solves This Problem 2Health News:New E-book Helps Nurses Identify and Prevent Three Most Common Healthcare Associated Infections 2Health News:New E-book Helps Nurses Identify and Prevent Three Most Common Healthcare Associated Infections 3Health News:AIIM Research Shows 56% of Organizations Not Utilizing Digital Archiving Technology 2Health News:AIIM Research Shows 56% of Organizations Not Utilizing Digital Archiving Technology 3Health News:AIIM Research Shows 56% of Organizations Not Utilizing Digital Archiving Technology 4
... rates in South, Southwest; lowest rates in Northeast, government reports ... rate in the United States increased in 26 of the ... country, according to a new government report. , Back ... Prevention reported that the teen birth rate for the entire ...
... recognized inpatient treatment center, is pleased to announce its plans ... is just a few of the ways Seabrook ... possible and that treatment works. Seabrook House,s vision is to ... to educate the public at large in an effort to ...
... Top Government Officials Will Explain Regulatory Plans for Cutting-Edge Technology ... , DC . WASHINGTON, Jan. 7 ... goods last year. By 2014, the market will grow to ... and therapeutics will be sold--up from more than $3 billion ...
... more and more Michigan residents,losing employer-sponsored health coverage, the ... To ease the burden, the Blue Cross,Blue Shield ... in matching,funds for projects that improve health care access ... "Fundable projects for the uninsured include creative and novel ...
... teenage boys don,t seem to be as susceptible, study suggests ... spend more than two hours of "screen time" a day ... to be physically fit, a new Australian study finds. , ... more likely to be able to "sit and be fit," ...
... COLUMBIA, Mo. There is no cure for spinal ... weakening of muscles and is the leading genetic cause ... discovered a new therapeutic target that improves deteriorating skeletal ... muscle strength, improved gross motor skills and increased the ...
Cached Medicine News:Health News:Teen Birth Rate Up in 26 States in 2006 2Health News:Seabrook House Embraces the New Year with New Programs 2Health News:Seabrook House Embraces the New Year with New Programs 3Health News:Food and Drug Law Institute Sponsors Major Conference on Nanotechnology Law, Regulation and Policy 2Health News:Food and Drug Law Institute Sponsors Major Conference on Nanotechnology Law, Regulation and Policy 3Health News:Food and Drug Law Institute Sponsors Major Conference on Nanotechnology Law, Regulation and Policy 4Health News:$1 Million Available to Help Michigan's Uninsured Receive Care 2Health News:More 'Screen Time' Linked to Poor Fitness in Girls 2Health News:Researchers discover target that could ease spinal muscular atrophy symptoms 2
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
25L...
This fixed-volume digital micropipet is used to accurately measure and transfer 50 microliters of solution....
50L...
Medicine Products: